Albany, NY -- (SBWIRE) -- 03/12/2013 -- TechNavio's analysts forecast the Global Kidney Cancer Drugs market to grow at a CAGR of 13.4 percent over the period 2012-2016. One of the key factors contributing to this market growth is the growing demand in developing economies. The Global Kidney Cancer Drugs market has also been witnessing an increase in R&D activities. However, over-dependence of the market on the US could pose a challenge to the growth of this market.
To Buy a Copy Of This Report: http://www.marketresearchreports.biz/analysis-details/global-kidney-cancer-drugs-market-2012-2016
TechNavio's report, Global Kidney Cancer Drugs Market 2012-2016, has been prepared based on an in-depth market analysis of the market with inputs from industry experts. The report covers the Americas, and the EMEA and APAC regions; it covers the Global Kidney Cancer Drugs market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.
For All Reports Kindly Visit: http://www.marketresearchreports.biz/
The key vendors dominating this market space are AVEO Pharmaceuticals Inc., Bayer AG, GlaxoSmithKline plc, Hoffmann-La Roche Ltd., Novartis AG, and Pfizer Inc.
The other vendors mentioned in the report are AstraZeneca plc, Onyx Pharmaceuticals Inc., Merck Serono S.A., and WILEX AG
To Read The Complete Report with TOC:http://www.marketresearchreports.biz/analysis/164353
Key questions answered in this report:
- What will the market size be in 2016 and what will the growth rate be?
- What are the key market trends?
- What is driving this market?
- What are the challenges to market growth?
- Who are the key vendors in this market space?
- What are the market opportunities and threats faced by the key vendors?
- What are the strengths and weaknesses of each of these key vendors?
Construction Chemicals Market in India 2012-2016: http://www.marketresearchreports.biz/analysis/164271
Global Mobile Collaboration Market 2012-2016: http://www.marketresearchreports.biz/analysis/164582